Originally published as JCO Early Release 10.1200/JCO.2007.12.0949 on September 17 2007
Journal of Clinical Oncology, Vol 25, No 29 (October 10), 2007: pp. 4557-4561
© 2007 American Society of Clinical Oncology.
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
Leonard B. Saltz,
Heinz-Josef Lenz,
Hedy L. Kindler,
Howard S. Hochster,
Scott Wadler,
Paulo M. Hoff,
Nancy E. Kemeny,
Ellen M. Hollywood,
Mithat Gonen,
Marcus Quinones,
Meroe Morse,
Helen X. Chen
From the Department of Biostatistics; Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; the Department of Medicine, Weill Medical College of Cornell University; Department of Medicine, New York University Cancer Institute, New York, NY; Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Chemotherapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD
Address reprint requests to Leonard B. Saltz, MD, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H-917, New York, NY 10021; e-mail: saltzl{at}MSKCC.ORG
Purpose We evaluated the safety and efficacy of concurrent administration of two monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal cancer.
Patients and Methods This was a randomized phase II study in patients with irinotecan-refractory colorectal cancer. All patients were naïve to both bevacizumab and cetuximab. Patients in arm A received irinotecan at the same dose and schedule as last received before study entry, plus cetuximab 400 mg/m2 loading dose, then weekly cetuximab 250 mg/m2, plus bevacizumab 5 mg/kg administered every other week. Patients in arm B received the same cetuximab and bevacizumab as those in arm A but without irinotecan.
Results Forty-three patients received cetuximab, bevacizumab, and irinotecan (CBI) and 40 patients received cetuximab and bevacizumab alone (CB). Toxicities were as would have been expected from the single agents. For the CBI arm, time to tumor progression (TTP) was 7.3 months and the response rate was 37%; for the CB arm, TTP was 4.9 months and the response rate was 20%. The overall survival for the CBI arm was 14.5 months and the overall survival for the CB-alone arm was 11.4 months.
Conclusion Cetuximab and bevacizumab can be administered concurrently, with a toxicity pattern that seems to be similar to that which would be expected from the two agents alone. This combination plus irinotecan also seems to be feasible. The activity seen with the addition of bevacizumab to cetuximab, or to cetuximab plus irinotecan, seems to be favorable when compared with historical controls of cetuximab or cetuximab/irinotecan in patients who are naïve to bevacizumab.
published online ahead of print at www.jco.org on September 17, 2007.
Supported by the Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI), under the collaborative agreement between CTEP, Genentech, ImClone, and Bristol-Myers Squibb Co: NCI Grants No. NO1-CM17105, NO1-CM17101, NO1-CM-17102, N01-CM-07003-CM74S, NO1-CM-17003.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
- Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet
José Baselga and Josep Tabernero
JCO 2007 25: 4516-4518
[Full Text]
Related Correspondence
- Bevacizumab: One Treatment for All the Seasons?
Alain J. Gelibter, Susanna Di Segni, Massimo Zeuli, and Francesco Cognetti
JCO 2008 26: 511
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
F. Loupakis, C. Cremolini, G. Fontanini, I. Stasi, L. Salvatore, and A. Falcone
Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Therapeutic Advances in Medical Oncology,
November 1, 2009;
1(3):
167 - 181.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology,
September 1, 2009;
1(2):
55 - 68.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. R. TONRA, E. CORCORAN, D. S. DEEVI, P. STEINER, J. KEARNEY, H. LI, D. L. LUDWIG, Z. ZHU, L. WITTE, D. SURGULADZE, et al.
Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models
Anticancer Res,
June 1, 2009;
29(6):
1999 - 2007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist,
May 1, 2009;
14(5):
478 - 488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. McCabe, L. Bergmann, N. Bosanquet, M. Ellis, H. Enzmann, M. von Euler, B. Jonsson, K.-J. Kallen, D. Newling, V. Nussler, et al.
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
Ann. Onc.,
March 1, 2009;
20(3):
403 - 412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, J. Marshall, A. Cohn, D. McCollum, P. Stella, et al.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Clin. Oncol.,
February 10, 2009;
27(5):
672 - 680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Blanke
Dual-Antibody Therapy in Advanced Colorectal Cancer: Gather Ye Rosebuds While Ye May
J. Clin. Oncol.,
February 10, 2009;
27(5):
655 - 658.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tol, M. Koopman, A. Cats, C. J. Rodenburg, G. J.M. Creemers, J. G. Schrama, F. L.G. Erdkamp, A. H. Vos, C. J. van Groeningen, H. A.M. Sinnige, et al.
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
N. Engl. J. Med.,
February 5, 2009;
360(6):
563 - 572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Mayer
Targeted Therapy for Advanced Colorectal Cancer -- More Is Not Always Better
N. Engl. J. Med.,
February 5, 2009;
360(6):
623 - 625.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shitara, M. Munakata, O. Muto, and Y. Sakata
Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report
Jpn. J. Clin. Oncol.,
July 1, 2008;
38(7):
493 - 496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tol, M. Koopman, C. J. Rodenburg, A. Cats, G. J. Creemers, J. G. Schrama, F. L. G. Erdkamp, A. H. Vos, L. Mol, N. F. Antonini, et al.
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Ann. Onc.,
April 1, 2008;
19(4):
734 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Gelibter, S. Di Segni, M. Zeuli, and F. Cognetti
Bevacizumab: One Treatment for All the Seasons?
J. Clin. Oncol.,
January 20, 2008;
26(3):
511 - 511.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Jonker, C. J. O'Callaghan, C. S. Karapetis, J. R. Zalcberg, D. Tu, H.-J. Au, S. R. Berry, M. Krahn, T. Price, R. J. Simes, et al.
Cetuximab for the Treatment of Colorectal Cancer
N. Engl. J. Med.,
November 15, 2007;
357(20):
2040 - 2048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Baselga and J. Tabernero
Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet
J. Clin. Oncol.,
October 10, 2007;
25(29):
4516 - 4518.
[Full Text]
[PDF]
|
|
|
|
